Awareness, Care & Treatment In Obesity Management - An International Observation Among Teens (ACTION Teens)

Sponsor
Novo Nordisk A/S (Industry)
Overall Status
Completed
CT.gov ID
NCT05013359
Collaborator
(none)
12,987
10
3.7
1298.7
352.9

Study Details

Study Description

Brief Summary

ACTION Teens is a multinational cross-sectional survey-based study. The study consists of a quantitative online survey to be conducted among three groups of respondents in ten countries worldwide. The respondent population will include Adolescents Living with Obesity (ALwO), Caregivers of ALwO, and HCPs treating adolescents who have obesity.

The goal of this study is to provide insights to drive awareness around the needs of adolescents living with obesity and their caregivers, as well as to identify key areas of misalignment between adolescents, their caregivers and the HCPs involved in obesity treatment and management. ACTION Teens is designed to generate evidence to identify and address these challenges on both a global and local level, extending the insights from the previously conducted ACTION-IO study.

Condition or Disease Intervention/Treatment Phase
  • Other: No treatment given

Study Design

Study Type:
Observational
Actual Enrollment :
12987 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Awareness, Care & Treatment In Obesity Management - An International Observation Among Teens (ACTION Teens)
Actual Study Start Date :
Aug 23, 2021
Actual Primary Completion Date :
Dec 13, 2021
Actual Study Completion Date :
Dec 13, 2021

Arms and Interventions

Arm Intervention/Treatment
Adolescents Living with Obesity (ALwO)

Recruited from online, general population consumer panels

Other: No treatment given
No treatment given

Health Care Providers (HCPs)

HCPs treating adolescents who have obesity

Other: No treatment given
No treatment given

Caregivers

A parent or legal guardian of an adolescent with obesity

Other: No treatment given
No treatment given

Outcome Measures

Primary Outcome Measures

  1. Attitudes about obesity, attitudes about people with obesity, and beliefs about the impact of obesity [At the time of survey response (Day 1)]

    5-point Likert scales (e.g., agreement, impact, frequency) - Proportion of responses in each category will be reported.

  2. Weight loss attempts in past year, motivations to lose weight, barriers to losing weight, and definition of successful weight loss/management [At the time of survey response (Day 1)]

    Yes/No; percentage of participants Multi-select from defined list - Percentage of respondents selecting an item or items will be reported.

  3. History and frequency of conversations about weight, initiator of weight conversations, and responsibility for initiating weight conversations that occur between adolescents living with obesity/their caregivers and healthcare providers [At the time of survey response (Day 1)]

    Numeric entry; percentage of participants Single select from defined list; percentage of time each initiates Single select from defined list

  4. Assessment of interactions between adolescents living with obesity/their caregivers and healthcare providers, reasons why obesity may not be discussed, frequency of obesity diagnosis, and frequency of follow-up appointments made to discuss obesity [At the time of survey response (Day 1)]

    5-point Likert scales Multi-select from defined list Yes/No; percentage of patients Yes/No; percentage of patients

  5. Sources of information used to learn about obesity, healthy lifestyles, weight loss, and weight management [At the time of survey response (Day 1)]

    Multi-select from defined list

Eligibility Criteria

Criteria

Ages Eligible for Study:
12 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria for Adolescents living with obesity:
  • Informed consent obtained by parent/legal guardian and ALwO before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).

  • Male or female, aged 12 to less than 18 years at the time of signing informed consent.

  • Lives in one of the participating countries: Italy, Spain, UK, Mexico, Colombia, Australia, Saudi Arabia, Turkey, South Korea, and Taiwan.

  • Has a current BMI-for-age (based on self-reported sex, age, height, and weight) greater than or equal to 95th percentile for age and sex based on charts appropriate locally for the country of residence.

Inclusion Criteria for Caregivers of Adolescents living with obesity:
  • Informed consent before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).

  • Male or female, age above or equal to 24 years at the time of signing informed consent.

  • Lives in one of the participating countries: Italy, Spain, UK, Mexico, Colombia, Australia, Saudi Arabia, Turkey, South Korea, and Taiwan.

  • Has an adolescent in the household with a current BMI-for-age (based on self-reported sex, age, height, and weight) greater than or equal to 95th percentile for age and sex based on charts appropriate locally for the country of residence.

  • Resides in the same household as the ALwO at least 50% of the time.

  • Is involved in the healthcare decisions of the ALwO.

Inclusion Criteria for Health Care Providers:
  • Informed consent before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).

  • Male or female, age above or equal to 18 years at the time of signing informed consent.

  • Is a physician.

  • Practices in one of the participating countries: Italy, Spain, UK, Mexico, Colombia, Australia, Saudi Arabia, Turkey, South Korea, and Taiwan

  • In clinical practice more than or equal to 2 years.

  • Spends at least 50% of time in direct patient care.

  • Has seen/treated at least ten adolescent patients (age 12 to less than 18 years) with obesity in a typical month (defined as BMI-for-age greater than or equal to 95th percentile for age and sex based on charts appropriate locally for the country of residence).

Exclusion Criteria for Adolescents living with obesity:
  • Previous participation in this study. Participation is defined as having given informed consent in this study.

  • Mental incapacity, unwillingness, inability, or language barriers precluding adequate understanding or cooperation.

  • Has had significant weight loss or weight gain due to major injury or illness/condition (e.g., cancer, accident, pregnancy) in the past 6 months.

  • Considers themselves to be extremely muscular.

Exclusion Criteria for Caregivers of Adolescents living with obesity:
  • Previous participation in this study. Participation is defined as having given informed consent in this study.

  • Mental incapacity, unwillingness, inability, or language barriers precluding adequate understanding or cooperation.

  • ALwO they care for has had significant weight loss or weight gain due to major injury or illness/condition (e.g., cancer, accident, pregnancy) in the past 6 months.

  • Considers the ALwO they care for to be extremely muscular.

Exclusion Criteria for Health Care Providers:
  • Previous participation in this study. Participation is defined as having given informed consent in this study.

  • Mental incapacity, unwillingness, inability, or language barriers precluding adequate understanding or cooperation.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Novo Nordisk Investigational Site Sydney Australia NSW 2060
2 Novo Nordisk Investigational Site Bogotá Colombia 110111
3 Novo Nordisk Investigational Site Rome Italy 00144
4 Novo Nordisk Investigational Site Seoul Korea, Republic of 05510
5 Novo Nordisk Investigational Site Mexico City Mexico 11560
6 Novo Nordisk Investigational Site Riyadh Saudi Arabia 13315
7 Novo Nordisk Investigational Site Madrid Spain 28033
8 Novo Nordisk Investigational Site Taipei Taiwan 106
9 Novo Nordisk Investigational Site Istanbul Turkey 34335
10 Novo Nordisk Investigational Site Gatwick United Kingdom RH6 0PA

Sponsors and Collaborators

  • Novo Nordisk A/S

Investigators

  • Study Director: Clinical Transparency (dept. 1452), Novo Nordisk A/S

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT05013359
Other Study ID Numbers:
  • DAS-003
  • U1111-1262-1190
First Posted:
Aug 19, 2021
Last Update Posted:
Feb 2, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 2, 2022